SAGE Therapeutics (SAGE)

SAGE Therapeutics (SAGE) Income Statement


SAGE Therapeutics Income Statement

Last quarter (Q3 2023), SAGE Therapeutics's total revenue was $2.72M, an increase of 56.18% from the same quarter last year. In Q3, SAGE Therapeutics's net income was $-199.82M. See SAGE Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 11.33M$ 7.69M$ 6.31M$ 1.11B$ 6.87M$ 90.27M
Cost of Revenue
---$ 565.00K$ 400.00K$ 0.00
Gross Profit
$ 11.35M$ 7.69M$ 6.31M$ 1.11B$ 6.47M$ 90.27M
Operating Expense
$ 703.03M$ 554.67M$ -467.22M$ 489.67M$ 714.59M$ 483.51M
Operating Income
$ -691.27M$ -546.99M$ -460.91M$ 623.97M$ -708.12M$ -393.24M
Net Non Operating Interest Income Expense
$ 36.07M$ 14.19M$ 2.88M$ 9.60M$ 27.80M$ 20.33M
Other Income Expense
$ 320.00K$ -15.00K$ -134.00K$ -27.49M$ 82.00K$ 22.00K
Pretax Income
$ -653.71M$ -531.16M$ -457.89M$ 606.07M$ -680.24M$ -372.88M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -654.12M$ -532.78M$ -457.89M$ 606.07M$ -680.24M$ -372.88M
Basic EPS
$ -13.05$ -8.98$ -7.80$ 11.66$ -13.38$ -8.08
Diluted EPS
$ -10.98$ -8.98$ -7.80$ 11.43$ -13.38$ -8.08
Basic Average Shares
$ 238.66M$ 59.31M$ 58.67M$ 51.98M$ 50.83M$ 46.12M
Diluted Average Shares
$ 238.66M$ 59.31M$ 58.67M$ 53.00M$ 50.83M$ 46.12M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 703.03M$ 554.67M$ -467.22M$ 490.23M$ 714.99M$ 483.51M
Net Income From Continuing And Discontinued Operation
$ -655.93M$ -532.78M$ -457.89M$ 606.07M$ -680.24M$ -372.88M
Normalized Income
$ -250.59M--$ 633.82M$ -680.24M$ -372.88M
Interest Expense
$ -669.33M$ -531.16M$ -460.77M$ 623.97M$ -708.12M$ -393.24M
$ -668.08M$ -530.06M$ -456.57M$ 626.60M$ -705.84M$ -392.10M
Currency in USD

SAGE Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis